Biotech Values

[mouton29]

<<That’s right. Teva’s first Copaxone CP was rejected by the FDA because it was filed prematurely and Teva’s second CP (the one referenced in my previous post) was rejected by the FDA on the merits>>

The law of symmetry demands that the FDA approve generic Copaxone and reject this CP on the ground it is moot.